ドコサヘキサエン酸富化Ｃｈｌｏｒｅｌｌａ　ｖｕｌｇａｒｉｓ　ＣＫ２２株のヒトにおける安全性および血清脂質濃度に対する影響の予備的検討

DOI Web Site 被引用文献3件 参考文献23件

書誌事項

タイトル別名
  • Preliminary Clinical Survey of the Docosahexaenoic Acid(DHA)-enriched Chlorella vulgaris Strain CK22 on Serum Lipid Levels and Its Safety Monitoring in Middle-aged Humans.
  • ドコサヘキサエンサン フカ Chlorella vulgaris CK22カブ ノ ヒト ニ オケル アンゼンセイ オヨビ ケッセイ シシツ ノウド ニ タイスル エイキョウ ノ ヨビテキ ケントウ

この論文をさがす

抄録

Chlorella vulgaris strain CK22 enriched with DHA (D-CVP) was examined for its safety and influence on serum lipid levels in 6 middle-aged participants. D-CVP was administered orally for 9 weeks. For the first 2 weeks, D-CVP 4g/day was supplemented with DHA 150mg. At 2-week intervals, D-CVP was increased progressively to 8 and 12g, after which 20g/day was administered for the last 3 weeks. At the start of the experiment, 5 of 6 and 1 of 6 subjects showed higher total cholesterol (T-CHO) and higher triglyceride levels, respectively, compared to the normal ranges. The 9 week-administration of D-CVP did not change the body weight, blood pressure or body mass index of any of the participants. The subjects' serum levels of DHA after D-CVP administration were different from those before administration. Although no change in T-CHO levels was observed after the first 3 weeks of administration, D-CVP had clearly lowered the T-CHO levels at 6 weeks. These lowered levels of T-CHO continued during the final 3 weeks of administration and beyond 3 weeks after administration. LDL-cholesterol, esterified cholesterol, and phospholipid showed the same patterns as T-CHO. HDL-cholesterol levels had decreased significantly at 9 weeks compared to the normal range. The D-CVP treatments did not change the other parameters of serum-biochemical and blood examination, and no adverse effects were observed in these experiments. D-CVP may be a candidate for prophylaxis of diseases caused by aging-related hyperlipidemia.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (23)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ